Premium
Bone marrow mononuclear cell thymidine uptake in chronic B‐lymphocytic leukaemia: Relation to prognosis
Author(s) -
Juliusson Gunnar,
Robèrt KarlHenrik
Publication year - 1986
Publication title -
scandinavian journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0036-553X
DOI - 10.1111/j.1600-0609.1986.tb01745.x
Subject(s) - thymidine , peripheral blood mononuclear cell , bone marrow , medicine , in vitro , gastroenterology , immunology , chemistry , biochemistry
The uptake of tritium‐labelled thymidine in bone marrow mononuclear cells from 22 untreated patients with Rai stage 0‐II chronic B‐lymphocytic leukaemia was analysed in 4‐d in vitro cultures. The thymidine uptakes showed a great interindividual variability; the counts per min ranged from 1100 to 80000 (mean 26360 ± 21800 cpm). Bone marrow cells from patients who needed treatment within 1 yr from diagnosis had a lower thymidine uptake than those from patients who were untreated for more than 2 yr (7820 ± 7420 and 34 300 ± 23 200 cpm, respectively, p < 0.001). Patients with low uptake cells had poorer prognosis than those with high uptake cells, both regarding survival (5‐yr probability: 0.6 and 1.0, respectively; p < 0.03) and therapy‐free survival (5‐yr probability: 0.36 and 1.0, respectively; p < 0.02).